<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168228">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987999</url>
  </required_header>
  <id_info>
    <org_study_id>GEN9892131</org_study_id>
    <nct_id>NCT01987999</nct_id>
  </id_info>
  <brief_title>Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor</brief_title>
  <official_title>Phase II Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate(ATP)Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Health Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the findings of an early study with prostate cancer
      and to expand our knowledge of treating prostate cancer using an
      Adenosine-5'-triphosphate(ATP)inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Gleason Score</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific  Antigens (PSA)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Acetogenins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetogenins twice (BID) per day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acetogenins</intervention_name>
    <arm_group_label>Acetogenins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of prostate cancer

          -  Referred to the study by their treating physician

        Exclusion Criteria:

        - Any type of treatment before starting study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Osguthorpe, ND</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimal Health Research</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
